PT - JOURNAL ARTICLE AU - David W. Redding AU - Rory Gibb AU - Chioma C. Dan-Nwafor AU - Elsie A. Ilori AU - Yashe Rimamdeyati Usman AU - Oladele H. Saliu AU - Amedu O. Michael AU - Iniobong Akanimo AU - Oladipupo B. Ipadeola AU - Lauren Enright AU - Christl A. Donnelly AU - Ibrahim Abubakar AU - Kate E. Jones AU - Chikwe Ihekweazu TI - Spatiotemporal analysis of surveillance data enables climate-based forecasting of Lassa fever AID - 10.1101/2020.11.16.20232322 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.16.20232322 4099 - http://medrxiv.org/content/early/2020/11/18/2020.11.16.20232322.short 4100 - http://medrxiv.org/content/early/2020/11/18/2020.11.16.20232322.full AB - Lassa fever (LF) is an acute rodent-borne viral haemorrhagic fever that is a longstanding public health concern in West Africa and increasingly a global health priority. Recent molecular studies1,2 have confirmed the fundamental role of the rodent host (Mastomys natalensis) in driving human infections, but LF control and prevention efforts remain hampered by a limited baseline understanding of the disease’s true incidence, geographical distribution and underlying drivers3. Here, through analysing 8 years of weekly case reports (2012-2019) from 774 local government authorities (LGAs) across Nigeria, we identify the socioecological correlates of LF incidence that together drive predictable, seasonal surges in cases. At the LGA-level, the spatial endemic area of LF is dictated by a combination of rainfall, poverty, agriculture, urbanisation and housing effects, although LF’s patchy distribution is also strongly impacted by reporting effort, suggesting that many infections are still going undetected. We show that spatial patterns of LF incidence within the endemic area, are principally dictated by housing quality, with poor-quality housing areas seeing more cases than expected. When examining the seasonal and inter-annual variation in incidence within known LF hotspots, climate dynamics and reporting effort together explain observed trends effectively (with 98% of observations falling within the 95% predictive interval), including the sharp uptick in 2018-19. Our models show the potential for forecasting LF incidence surges 1-2 months in advance, and provide a framework for developing an early-warning system for public health planning.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIt is not a clinical trialFunding StatementThis research was supported by an MRC UKRI/Rutherford Fellowship (MR/R02491X/1) and Wellcome Trust Institutional Strategic Support Fund (204841/Z/16/Z) (both DWR), a Graduate Research Scholarship (RG) and Global Engagement Fund grant (DWR, RG) both from University College London, and the Natural Environment Research Council (NERC) PhD studentship (LE). CAD acknowledges joint Centre funding from the UK Medical Research Council and Department for International Development (DFID). CAD is funded by the Department of Health and Social Care using UK Aid funding on a grant managed by the UK National Institute for Health Research (NIHR). The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care. IA acknowledges funding from the UK NIHR (NF-SI-0616-10037), EDCTP PANDORA Consortium and the UK MRC. KEJ acknowledges the Dynamic Drivers of Disease in Africa Consortium, NERC project no. NE-J001570-1 which was funded with support from the Ecosystem Services for Poverty Alleviation Programme (ESPA). The ESPA programme was funded by DFID, the Economic and Social Research Council (ESRC) and NERC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Uses existing anonymised data aggregated at district level - no oversight needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available in an online repository upon publication acceptance.